Invention Grant
US08716480B2 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
有权
7-芳基-1,2,4-三唑并[4,3-a]吡啶衍生物及其作为mGluR2受体的正变构调节剂的用途
![7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors](/docs/US/2014-05-06/US08716480B2/abs.jpg.600x600.jpg)
- Patent Title: 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
- Patent Title (中): 7-芳基-1,2,4-三唑并[4,3-a]吡啶衍生物及其作为mGluR2受体的正变构调节剂的用途
-
Application No.: US13319568Application Date: 2010-05-11
-
Publication No.: US08716480B2Publication Date: 2014-05-06
- Inventor: Jose Maria Cid-Nunez , Ana Isabel De Lucas Olivares , Andres Avelino Trabanco-Suarez , Gregor James MacDonald
- Applicant: Jose Maria Cid-Nunez , Ana Isabel De Lucas Olivares , Andres Avelino Trabanco-Suarez , Gregor James MacDonald
- Applicant Address: US NJ Titusville CH Geneva
- Assignee: Janssen Pharmaceuticals, Inc.,Addex Pharma, SA
- Current Assignee: Janssen Pharmaceuticals, Inc.,Addex Pharma, SA
- Current Assignee Address: US NJ Titusville CH Geneva
- Agency: Baker & Hostetler LLP
- Priority: EP09160064 20090512; WOPCT/EP2010/002909 20100511
- International Application: PCT/EP2010/002909 WO 20100511
- International Announcement: WO2010/130423 WO 20101118
- Main IPC: C07D215/38
- IPC: C07D215/38
![7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors](/abs-image/US/2014/05/06/US08716480B2/abs.jpg.150x150.jpg)
Abstract:
The present invention relates to novel triazolo[4,3-a]pyridine derivatives of Formula (I) wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (“mGluR2”), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.
Public/Granted literature
Information query
